Please assess the completion status of the following clinical trial:

Trial Title: LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented stable chronic heart failure (NYHA II-IV):~  * LVEF ≥ 45% (local measurement, assessed by echocardiography, MUGA, CT scan, MRI or ventricular angiography)~ * the ejection fraction must have been obtained within 6 months prior to randomization or after any MI or other event that would affect ejection fraction.~* Plasma NT-proBNP \> 500 pg/ml at Visit 1.~* Patients with documented stable chronic heart failure (NYHA II-IV).~* Patients receiving ACE inhibitors (ACEi), an angiotensin receptor blockers (ARB) and/or a beta blockers must be on a stable dose of these medications stable for the 1 month period prior to Visit 1.~* Patients must be on diuretic therapy prior to Visit 1 (flexible dosing is permitted).~* Patients with a controlled systolic BP, defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP at randomization (Visit 2).~* Patients with at least one of the following symptoms at the time of screening (Visit 1):~  * Dyspnea on exertion~ * Orthopnea~ * Paroxysmal nocturnal dyspnea~ * Peripheral edema~* Patients must have an eGFR ≥ 30 ml/min/1.73 m2 at Visit 1 (calculated by the Modification of Diet in Renal Disease formula).~* Patients with a potassium ≤5.2 mmol/l at Visit 1.~Exclusion Criteria:~* Patients with a prior LVEF reading \<45%, at any time.~* Patients who require treatment with both an ACE inhibitor and an ARB.~* Isolated right heart failure due to pulmonary disease.~* Dyspnea and/or edema from non-cardiac causes, such as lung disease, anemia, or severe obesity.~* Presence of hemodynamically significant mitral and /or aortic valve disease.~* Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.~* Presence of hypertrophic obstructive cardiomyopathy.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
- Valsartan (Type: ACTIVE_COMPARATOR): During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.

Based on this trial design, predict the completion outcome and termination type (if applicable).